Should all papillary thyroid microcarcinomas be aggressively treated?: An analysis of 18,445 cases

Annals of Surgery

Volumn 254, Issue 4, 2011, Pages 653-660

  Yu, Xiao Min ^a   Wan, Yin ^a   Sippel, Rebecca S ^a   Chen, Herbert ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; CANCER INVASION; CANCER MORTALITY; CANCER SURVIVAL; CONFERENCE PAPER; DISEASE SPECIFIC SURVIVAL; DISTANT METASTASIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PAPILLARY THYROID MICROCARCINOMA; PRIORITY JOURNAL; RISK FACTOR; THYROID CARCINOMA; THYROIDECTOMY; TUMOR VOLUME;

ADULT; CARCINOMA, PAPILLARY; COHORT STUDIES; FEMALE; HUMANS; MALE; MULTIVARIATE ANALYSIS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 80053272812     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e318230036d     Document Type: Conference Paper

References (36)

1. National Cancer Institute. SEER Cancer Statistics Review 1975-2007. http://seer.cancer.gov/csr/1975-2007/browse-csr.php?section = 26&page = sect-26-table.05.html. Accessed March 6, 2011 2010.
2. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006;295:2164-2167.
3. Cramer JD, Fu P, Harth KC, et al. Analysis of the rising incidence of thyroid cancer using the Surveillance, Epidemiology and End Results national cancer data registry. Surgery. 2010;148:1147-1152; discussion 1152-1153.
4. Haymart MR, Cayo M, Chen H. Papillary thyroid microcarcinomas: big decisions for a small tumor. Ann Surg Oncol. 2009;16:3132-3139.
5. Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16:109-142.
6. Pacini F, Schlumberger M, Dralle H, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154:787-803. (Pubitemid 43997716)
7. Ito Y, Uruno T, Nakano K, et al. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid. 2003;13:381-387. (Pubitemid 36588523)
8. Wada N, Duh QY, Sugino K, et al. Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann Surg. 2003;237:399-407. (Pubitemid 38176456)
9. Pellegriti G, Scollo C, Lumera G, et al. Clinical behavior and outcome of papillary thyroid cancers smaller than 1.5 cm in diameter: study of 299 cases. J Clin Endocrinol Metab. 2004;89:3713-3720. (Pubitemid 39071462)
10. So YK, Son YI, Hong SD, et al. Subclinical lymph node metastasis in papillary thyroid microcarcinoma: a study of 551 resections. Surgery. 2010;148:526-531.
11. Sherman SI. Thyroid carcinoma. Lancet. 2003;361:501-511. (Pubitemid 36173719)
12. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Mannual. 6th edition. New York, NY: Springer-Verlag, 2002.
13. Sugitani I, Toda K, Yamada K, et al. Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes. World J Surg. 2010;34:1222-1231.
14. Nathan H, Pawlik TM. Limitations of claims and registry data in surgical oncology research. Ann Surg Oncol. 2008;15:415-423.
15. Gaur P, Leary C, Yao JC. Thymic neuroendocrine tumors: a SEER database analysis of 160 patients. Ann Surg. 2010;251:1117-1121.
16. Fritz AG. International Classification of Disease for Oncology: ICD-O. 3rd ed. Geneva, Switzerland: World Health Organization, 2000.
17. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361-387. (Pubitemid 26072233)
18. Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery. 1988;104:947-953. (Pubitemid 19011971)
19. Chow SM, Law SC, Chan JK, et al. Papillary microcarcinoma of the thyroid-prognostic significance of lymph node metastasis and multifocality. Cancer. 2003;98:31-40. (Pubitemid 36741122)
20. Hay ID, Grant CS, van Heerden JA, et al. Papillary thyroid microcarcinoma: a study of 535 cases observed in a 50-year period. Surgery. 1992;112:1139-1146; discussion 1146-1147.
21. Baudin E, Travagli JP, Ropers J, et al. Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience. Cancer. 1998;83:553-559. (Pubitemid 28354512)
22. Page C, Biet A, Boute P, et al. "Aggressive papillary" thyroid microcarcinoma. Eur Arch Otorhinolaryngol. 2009;266:1959-1963.
23. Mercante G, Frasoldati A, Pedroni C, et al. Prognostic factors affecting neck lymph node recurrence and distant metastasis in papillary microcarcinoma of the thyroid: results of a study in 445 patients. Thyroid. 2009;19:707-716.
24. Hundahl SA, Fleming ID, Fremgen AM, et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see comments]. Cancer. 1998;83:2638-2648. (Pubitemid 29019586)
25. Sugitani I, Yanagisawa A, Shimizu A, et al. Clinicopathologic and immuno-histochemical studies of papillary thyroid microcarcinoma presenting with cervical lymphadenopathy. World J Surg. 1998;22:731-737. (Pubitemid 28277870)
26. Appetecchia M, Scarcello G, Pucci E, et al. Outcome after treatment of papillary thyroid microcarcinoma. J Exp Clin Cancer Res. 2002;21:159-164. (Pubitemid 34785548)
27. Lo CY, Chan WF, Lang BH, et al. Papillary microcarcinoma: is there any difference between clinically overt and occult tumors? World J Surg. 2006;30:759-766. (Pubitemid 43724103)
28. Besic N, Zgajnar J, Hocevar M, et al. Extent of thyroidectomy and lym-phadenectomy in 254 patients with papillary thyroid microcarcinoma: a single-institution experience. Ann Surg Oncol. 2009;16:920-928.
29. Lombardi CP, Bellantone R, De Crea C, et al. Papillary thyroid microcarci-noma: extrathyroidal extension, lymph node metastases, and risk factors for recurrence in a high prevalence of goiter area. World J Surg. 2010;34:1214-1221.
30. Sellers M, Beenken S, Blankenship A, et al. Prognostic significance of cervical lymph node metastases in differentiated thyroid cancer. Am J Surg. 1992;164:578-581.
31. Mazzaferri EL, Young RL. Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients. Am J Med. 1981;70:511-518. (Pubitemid 11153883)
32. Pearce EN, Braverman LE. Papillary thyroid microcarcinoma outcomes and implications for treatment. J Clin Endocrinol Metab. 2004;89:3710-3712. (Pubitemid 39071461)
33. Cheema Y, Olson S, Elson D, et al. What is the biology and optimal treatment for papillary microcarcinoma of the thyroid? J Surg Res. 2006;134: 160-162. (Pubitemid 44092824)
34. Lin JD, Chao TC, Hsueh C, et al. High recurrent rate of multicentric papillary thyroid carcinoma. Ann Surg Oncol. 2009;16:2609-2616.
35. Xing M. BRAF mutation in papillary thyroid microcarcinoma: the promise of better risk management. Ann Surg Oncol. 2009;16:801-803.
36. Melck AL, Yip L, Carty SE. The utility of BRAF testing in the management of papillary thyroid cancer. Oncologist. 2010;15:1285-1293.